Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study

Am J Respir Crit Care Med. 2009 Nov 1;180(9):861-6. doi: 10.1164/rccm.200812-1912OC. Epub 2009 Aug 20.

Abstract

Rationale: Several Surviving Sepsis Campaign Guidelines recommendations are reevaluated.

Objectives: To analyze the effectiveness of treatments recommended in the sepsis guidelines.

Methods: In a prospective observational study, we studied all adult patients with severe sepsis from 77 intensive care units. We recorded compliance with four therapeutic goals (central venous pressure 8 mm Hg or greater for persistent hypotension despite fluid resuscitation and/or lactate greater than 36 mg/dl, central venous oxygen saturation 70% or greater for persistent hypotension despite fluid resuscitation and/or lactate greater than 36 mg/dl, blood glucose greater than or equal to the lower limit of normal but less than 150 mg/dl, and inspiratory plateau pressure less than 30 cm H(2)O for mechanically ventilated patients) and four treatments (early broad-spectrum antibiotics, fluid challenge in the event of hypotension and/or lactate greater than 36 mg/dl, low-dose steroids for septic shock, drotrecogin alfa [activated] for multiorgan failure). The primary outcome measure was hospital mortality. The effectiveness of each treatment was estimated using propensity scores.

Measurements and main results: Of 2,796 patients, 41.6% died before hospital discharge. Treatments associated with lower hospital mortality were early broad-spectrum antibiotic treatment (treatment within 1 hour vs. no treatment within first 6 hours of diagnosis; odds ratio, 0.67; 95% confidence interval, 0.50-0.90; P = 0.008) and drotrecogin alfa (activated) (odds ratio, 0.59; 95% confidence interval, 0.41-0.84; P = 0.004). Fluid challenge and low-dose steroids showed no benefits.

Conclusions: In severe sepsis, early administration of broad-spectrum antibiotics in all patients and administration of drotrecogin alfa (activated) in the most severe patients reduce mortality.

Publication types

  • Multicenter Study

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Infective Agents / therapeutic use*
  • Cohort Studies
  • Female
  • Fluid Therapy / methods*
  • Follow-Up Studies
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Prospective Studies
  • Protein C / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Sepsis / drug therapy
  • Sepsis / therapy*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated